Literature DB >> 1850610

Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study.

M S Heier1, T Nilsen, V Graver, N Aass, S D Fosså.   

Abstract

The pathophysiology of Raynaud's phenomenon after Cisplatin-Bleomycin-Vinblastine combination chemotherapy, its relationship to polyneuropathy, and response to transcutaneous nerve stimulation (TNS), was studied in eight patients previously treated for testicular cancer. Peripheral circulation in the index finger was measured by laser Doppler flowmetry before and after cold provocation. In all patients there was an exaggerated and prolonged vasoconstrictor response to cold, with a mean flux reduction of 61%, and a mean restitution time of greater than 7 min, characteristic of Raynaud's phenomenon of the vasospastic type. The normal controls had a mean flux reduction of 24% and a restitution time of 1.5 min. Clinical examination and nerve conduction measurements revealed a mild polyneuropathy in five of the eight patients, but an etiological relationship with Raynaud's phenomenon could not be ascertained. There was no measurable effect of TNS.

Entities:  

Mesh:

Year:  1991        PMID: 1850610      PMCID: PMC1972340          DOI: 10.1038/bjc.1991.129

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold.

Authors:  S W Hansen; N Olsen
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

2.  Vincristine neuropathy. Clinical and electrophysiological observations.

Authors:  E B Casey; A M Jellife; P M Le Quesne; Y L Millett
Journal:  Brain       Date:  1973       Impact factor: 13.501

3.  Raynaud's phenomenon, histamine, and prostaglandins.

Authors:  D F Horrobin; K Jenkins; M S Manku
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

4.  In search of mediators of skin vasodilation induced by transcutaneous nerve stimulation: III. Increase in plasma VIP in normal subjects and in Raynaud's disease.

Authors:  B Kaada; E Olsen; O Eielsen
Journal:  Gen Pharmacol       Date:  1984

5.  On the nature of Raynaud's phenomenon: the role of histamine.

Authors:  K Lafferty; J C De Trafford; V C Roberts; L T Cotton
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

6.  Evaluation of skin vasomotor reflexes by using laser Doppler velocimetry.

Authors:  P A Low; C Neumann; P J Dyck; R D Fealey; R R Tuck
Journal:  Mayo Clin Proc       Date:  1983-09       Impact factor: 7.616

7.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.

Authors:  N J Vogelzang; G J Bosl; K Johnson; B J Kennedy
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

8.  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.

Authors:  N J Vogelzang; J L Torkelson; B J Kennedy
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

9.  Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome.

Authors:  E J Keenan; J M Porter
Journal:  Surgery       Date:  1983-08       Impact factor: 3.982

10.  Long-term somatic side-effects and morbidity in testicular cancer patients.

Authors:  N Aass; S Kaasa; E Lund; O Kaalhus; M S Heier; S D Fosså
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

View more
  2 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

2.  Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas.

Authors:  H M Earl; S Connolly; C Latoufis; K Eagle; C M Ash; C Fowler; R L Souhami
Journal:  Sarcoma       Date:  1998
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.